Ovarian germ cell malignancies: the Yale University experience.
Schwartz
P E
PE
Chambers
S K
SK
Chambers
J T
JT
Kohorn
E
E
McIntosh
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D003609:Dactinomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D005260:Female; D005298:Fertility / Q000187:drug effects; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016879:Salvage Therapy; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards
D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin